Modern view on the effectiveness and safety of non-steroidal anti-inflammatory drugs

Abstract

Issues of the effectiveness and safety of drugs remain relevant and controversial. The benefits and risks of drug therapy are two facets of one whole, called pharmacotherapy, which can have undesirable side and even negatively outweigh the benefits. The effectiveness and safety of drugs must be studied comprehensively because new effects of drugs may be discovered and new mechanisms for unregistered indications may be revealed. Moreover, a deep understanding of adverse drug reactions will allow for the accurate prescription of drugs and proper medical supervision of therapy. Nonsteroidal anti-inflammatory drugs are over-the-counter drugs perceived by patients as safe and do not require a doctor’s prescription, which can cause dangerous drug reactions, particularly when used uncontrollably. The review presents literature data from studies on the effectiveness of nonsteroidal anti-inflammatory drugs and current data on new therapeutic effects of individual drugs, risks of adverse reactions, their mechanisms, and treatment methods.

Keywords

nonsteroidal anti-inflammatory drugs / analgesia / NSAID gastropathy / cardiovascular complications / nephropathy / bronchial obstruction

References

[1] Karateev AE, Nasonov EL, Ivashkin VT, et al. Rational use of nonsteroidal anti-inflammatory drugs. Clinical guidelines. Rheumatology Science and Practice. 2018;56:1–29. EDN: PCPKRP doi: 10.14412/1995-4484-2018-1-29

[2] Каратеев А.Е., Насонов Е.Л., Ивашкин В.Т., и др. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации // Научно-практическая ревматология. 2018. Т. 56. С. 1–29. doi: 10.14412/1995-4484-2018-1-29

[3] Cooney MF. Pain management in children: NSAID Use in the perioperative and emergency department settings. Pediatr Drugs. 2021;23:361–372. doi: 10.1007/s40272-021-00449-z

[4] Cooney M.F. Pain management in children: NSAID Use in the perioperative and emergency department settings // Pediatr Drugs. 2021. Vol. 23. P. 361–372. doi: 10.1007/s40272-021-00449-z

[5] Balabanova RM, Dubinina TV. Five-year (2013–2017) trends in the incidence and prevalence of musculoskeletal system diseases among the adult population of Russia. Modern Rheumatology Journal. 2019;13(4):11–17. EDN: VFVQEE doi: 10.14412/1996-7012-2019-4-11-17

[6] Балабанова Р.М., Дубинина Т.В. Динамика пятилетней заболеваемости болезнями костно-мышечной системы и их распространенности среди взрослого населения России за 2013–2017 гг. // Современная ревматология. 2019. Т. 13, № 4. С. 11–17. EDN: VFVQEE doi: 10.14412/1996-7012-2019-4-11-17

[7] Balabanova RM, Dubinina TV, Demina AV, Krichevskaya OA. The incidence of musculoskeletal diseases in the Russian Federation over 2015–2016. Rheumatology Science and Practice. 2018;56(1):15–21. EDN: XPLNLF doi: 10.14412/1995-4484-2018-15-21

[8] Балабанова Р.М., Дубинина Т.В., Демина А.Б., Кричевская О.А. Заболеваемость болезнями костно-мышечной системы в Российской Федерации в 2015–2016 гг. // Научно-практическая ревматология. 2018. Т. 56, № 1. С. 15–21. EDN: XPLNLF doi: 10.14412/1995-4484-2018-15-21

[9] Nasonov EL. Russian clinical recommendations. Rheumatology. Moscow: GEOTAR-Media; 2017. 464 p. (In Russ.)

[10] Насонов Е.Л. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа, 2017. 464 с.

[11] Nasonov EL, Yakhno NN, Karateev AE, et al. General principles of treatment for musculoskeletal pain: interdisciplinary consensus. Rheumatology Science and Practice. 2016;54(3):247–265. EDN: WXHGNX doi: 10.14412/1995-4484-2016-247-265

[12] Насонов Е.Л., Яхно Н.Н., Каратеев А.Е., и др. Общие принципы лечения скелетно-мышечной боли: междисциплинарный консенсус // Научно-практическая ревматология. 2016. Т. 54, № 3. С. 247–265. EDN: WXHGNX doi: 10.14412/1995-4484-2016-247-265

[13] Bosch DJ, Nieuwenhuijs-Moeke GJ, van Meurs M, et al. Immune modulatory effects of nonsteroidal anti-inflammatory drugs in the perioperative period and their consequence on postoperative outcome. Anesthesiology. 2022;136:843–860. doi: 10.1097/ALN.0000000000004141

[14] Bosch D.J., Nieuwenhuijs-Moeke G.J., van Meurs M., et al. Immune modulatory effects of nonsteroidal anti-inflammatory drugs in the perioperative period and their consequence on postoperative outcome // Anesthesiology. 2022. Vol. 136. P. 843–860. doi: 10.1097/ALN.0000000000004141

[15] Serebrennikova SN, Seminsky IZh, Guzovskaiia EV, Gutsol LO. Inflammation as a fundamental pathological process: lecture 2 (cellular component). Baikal Medical Journal. 2023;2(2):65–76. EDN: ALTEJQ doi: 10.57256/2949-0715-2023-2-65-76

[16] Серебренникова С.Н., Семинский И.Ж., Гузовская Е.В., Гуцол Л.О. Воспаление — фундаментальный патологический процесс: лекция 2 (клеточные реакции) // Байкальский медицинский журнал. 2023. Т. 2, № 2. С. 65–76. EDN: ALTEJQ doi: 10.57256/2949-0715-2023-2-65-76

[17] Karateev AE, Uspensky YuP, Pakhomova IG, Nasonov EL. A concise course of the history of NSAIDs. Rheumatology Science and Practice. 2012;50(3):101–116. EDN: PLWYPR doi: 10.14412/1995-4484-2012-718

[18] Каратеев А.Е., Успенский Ю.П., Пахомова И.Г., Насонов Е.Л. Краткий курс истории НПВП // Научно-практическая ревматология. 2012. Т. 50, № 3. С. 101–116. EDN: PLWYPR doi: 10.14412/1995-4484-2012-718

[19] Wikipedia: [Electronic resource] URL: https://ru.wikipedia.org/wiki/%D0%9F%D1%80%D0%BE%D1%81%D1%82%D0%B0%D0%B3%D0%BB%D0%B0%D0%BD%D0%B4%D0%B8%D0%BD%D1%8B (cited 01 Feb 2024)

[20] Википедия: [Электронный ресурс] Режим доступа: https://ru.wikipedia.org/wiki/%D0%9F%D1%80%D0%BE%D1%81%D1%82%D0%B0%D0%B3%D0%BB%D0%B0%D0%BD%D0%B4%D0%B8%D0%BD%D1%8B (Дата обращения 02.01.2024)

[21] Godzenko AA, Godzenko MV. The role of nonsteroidal anti-inflammatory drugs in the treatment of spondylarthritis. Effective pharmacotherapy. 2019;15(23):6–10. EDN: RITULZ doi: 10.33978/2307-3586-2019-15-23-6-10

[22] Годзенко А.А., Годзенко М.В. Роль нестероидных противовоспалительных препаратов в лечении спондилоартритов // Эффективная фармакотерапия. 2019. Т. 15, № 23. С. 6–10. EDN: RITULZ doi: 10.33978/2307-3586-2019-15-23-6-10

[23] Gilligan MM, Gartung A, Sulciner ML, et al. Aspirin-triggered proresolving mediators stimulate resolution in cancer. PNAS USA. 2019;116(13):6292–6297. doi: 10.1073/pnas.1804000116

[24] Gilligan M.M., Gartung A., Sulciner M.L., et al. Aspirin-triggered proresolving mediators stimulate resolution in cancer // PNAS USA. 2019. Vol. 116, N 13. P. 6292–6297. doi: 10.1073/pnas.1804000116

[25] Karateev AE, Aleinikova TL. Eicosanoids and inflammation. Modern Rheumatology Journal. 2016;10(4):73–86. EDN: XEKFCP doi: 10.14412/1996-7012-2016-4-73-86

[26] Каратеев А.Е., Алейникова Т.Л. Эйкозаноиды и воспаление // Современная ревматология. 2016. Т. 10, № 4. С. 73–86. EDN: XEKFCP doi: 10.14412/1996-7012-2016-4-73-86

[27] Serhan CN, Levy BD. Resolvins in inflammation: Emergence of the pro-resolving superfamily of mediators. J Clin Invest. 2018;128(7):2657–2669. doi: 10.1172/JCI97943

[28] Serhan C.N., Levy B.D. Resolvins in inflammation: Emergence of the pro-resolving superfamily of mediators // J Clin Invest. 2018. Vol. 128, N 7. P. 2657–2669. doi: 10.1172/JCI97943

[29] Wall T, Sherwin A, Ma D, Buggy DJ. Influence of perioperative anaesthetic and analgesic interventions on oncological outcomes: A narrative review. Br J Anaesth. 2019;123(2):135–150. doi: 10.1016/j.bja.2019.04.062

[30] Wall T., Sherwin A., Ma D., Buggy D.J. Influence of perioperative anaesthetic and analgesic interventions on oncological outcomes: A narrative review // Br J Anaesth. 2019. Vol. 123, N 2. P. 135–150. doi: 10.1016/j.bja.2019.04.062

[31] Ma W, Wang K, Du J, et al. Multi-dose parecoxib provides an immunoprotective effect by balancing T helper 1 (Th1), Th2, Th17 and regulatory T cytokines following laparoscopy in patients with cervical cancer. Mol Med Rep. 2015;11(4):2999–3008. doi: 10.3892/mmr.2014.3003

[32] Ma W., Wang K., Du J., et al. Multi-dose parecoxib provides an immunoprotective effect by balancing T helper 1 (Th1), Th2, Th17 and regulatory T cytokines following laparoscopy in patients with cervical cancer // Mol Med Rep. 2015. Vol. 11, N 4. P. 2999–3008. doi: 10.3892/mmr.2014.3003

[33] Kaufmann KB, Heinrich S, Staehle HF, et al. Perioperative cytokine profile during lung surgery predicts patients at risk for postoperative complications: A prospective, clinical study. PLoS One. 2018;13: e0199807. doi: 10.1371/journal.pone.0199807

[34] Kaufmann K.B., Heinrich S., Staehle H.F., et al. Perioperative cytokine profile during lung surgery predicts patients at risk for postoperative complications: A prospective, clinical study // PLoS One. 2018. Vol. 13. ID e0199807. doi: 10.1371/journal.pone.0199807

[35] Leijte GP, Kiers D, van der Heijden W, et al. Treatment with acetylsalicylic acid reverses endotoxin tolerance in humans in vivo: A randomized placebo-controlled study. Crit Care Med. 2019;47(4):508–516. doi: 10.1097/CCM.0000000000003630

[36] Leijte G.P., Kiers D., van der Heijden W., et al. Treatment with acetylsalicylic acid reverses endotoxin tolerance in humans in vivo: A randomized placebo-controlled study // Crit Care Med. 2019. Vol. 47, N. 4. P. 508–516. doi: 10.1097/CCM.0000000000003630

[37] Kiers D, van der Heijden WA, van Ede L, et al. A randomised trial on the effect of anti-platelet therapy on the systemic inflammatory response in human endotoxaemia. Thromb Haemost. 2017;117(9):1798–1807. doi: 10.1160/th16-10-0799

[38] Kiers D., van der Heijden W.A., van Ede L., et al. A randomised trial on the effect of anti-platelet therapy on the systemic inflammatory response in human endotoxaemia // Thromb Haemost. 2017. Vol. 117, N 9. P. 1798–1807. doi: 10.1160/th16-10-0799

[39] Trauer J, Muhi S, McBryde ES, et al. Quantifying the effects of prior acetyl-salicylic acid on sepsis-related deaths: An individual patient data meta-analysis using propensity matching. Crit Care Med. 2017;45(11):1871–1879. doi: 10.1097/ccm.0000000000002654

[40] Trauer J., Muhi S., McBryde E.S., et al. Quantifying the effects of prior acetyl-salicylic acid on sepsis-related deaths: An individual patient data meta-analysis using propensity matching // Crit Care Med. 2017. Vol. 45, N 11. P. 1871–1879. doi: 10.1097/ccm.0000000000002654

[41] Eisen DP, Leder K, Woods RL, et al. Effect of aspirin on deaths associated with sepsis in healthy older people (ANTISEPSIS): A randomised, double-blind, placebo-controlled primary prevention trial. Lancet Respir Med. 2021;9(2):186–195. doi: 10.1016/s2213-2600(20)30411-2

[42] Eisen D.P., Leder K., Woods R.L., et al. Effect of aspirin on deaths associated with sepsis in healthy older people (ANTISEPSIS): A randomised, double-blind, placebo-controlled primary prevention trial // Lancet Respir Med. 2021. Vol. 9, N 2. P. 186–195. doi: 10.1016/s2213-2600(20)30411-2

[43] Elia N, Lysakowski C, Tramèr MR. Does multimodal analgesia with acetaminophen, nonsteroidal antiinflammatory drugs, or selective cyclooxygenase-2 inhibitors and patient-controlled analgesia morphine offer advantages over morphine alone?: Meta-analyses of randomized trials. Anesthesiology. 2005;103:1296–1304. doi: 10.1097/00000542-200512000-00025

[44] Elia N., Lysakowski C., Tramèr M.R. Does multimodal analgesia with acetaminophen, nonsteroidal antiinflammatory drugs, or selective cyclooxygenase-2 inhibitors and patient-controlled analgesia morphine offer advantages over morphine alone?: Meta-analyses of randomized trials // Anesthesiology. 2005. Vol. 103. P. 1296–1304. doi: 10.1097/00000542-200512000-00025

[45] Maund E, McDaid C, Rice S, et al. Paracetamol and selective and non-selective non-steroidal anti-inflammatory drugs for the reduction in morphine-related side-effects after major surgery: A systematic review. Br J Anaesth. 2011;106(3):292–297. doi: 10.1093/bja/aeq406

[46] Maund E., McDaid C., Rice S., et al. Paracetamol and selective and non-selective non-steroidal anti-inflammatory drugs for the reduction in morphine-related side-effects after major surgery: A systematic review // Br J Anaesth. 2011. Vol. 106, N 3. P. 292–297. doi: 10.1093/bja/aeq406

[47] Marret E, Kurdi O, Zufferey P, Bonnet F. Effects of nonsteroidal antiinflammatory drugs on patient-controlled analgesia morphine side effects: Meta-analysis of randomized controlled trials. Anesthesiology. 2005;102:1249–1260. doi: 10.1097/00000542-200506000-00027

[48] Marret E., Kurdi O., Zufferey P., Bonnet F. Effects of nonsteroidal antiinflammatory drugs on patient-controlled analgesia morphine side effects: Meta-analysis of randomized controlled trials // Anesthesiology. 2005. Vol. 102. P. 1249–1260. doi: 10.1097/00000542-200506000-00027

[49] Yang P-M, Liu Y-L, Lin Y-C, et al. Inhibition of autophagy enhances anticancer effects of atorvastatin in digestive malignancies. Cancer Res. 2010;70(19):7699–7709. doi: 10.1158/0008-5472.can-10-1626

[50] Yang P.-M., Liu Y.-L., Lin Y.-C., et al. Inhibition of autophagy enhances anticancer effects of atorvastatin in digestive malignancies // Cancer Res. 2010. Vol. 70, N 19. P. 7699–7709. doi: 10.1158/0008-5472.can-10-1626

[51] Guo L, Gao J, Gao Y, et al. Aspirin reshapes acetylomes in inflammatory and cancer cells via CoA-Dependent and CoA-independent pathways. J Proteome Res. 2020;19(2):962–972. doi: 10.1021/acs.jproteome.9b00853

[52] Guo L., Gao J., Gao Y., et al. Aspirin reshapes acetylomes in inflammatory and cancer cells via CoA-Dependent and CoA-independent pathways // J Proteome Res. 2020. Vol. 19, N 2. P. 962–972. doi: 10.1021/acs.jproteome.9b00853

[53] Chen WY, Holmes MD. Role of aspirin in breast cancer survival. Curr Oncol Rep. 2017;19(7):48. doi: 10.1007/s11912-017-0605-6

[54] Chen W.Y., Holmes M.D. Role of aspirin in breast cancer survival // Curr Oncol Rep. 2017. Vol. 19, N 7. ID 48. doi: 10.1007/s11912-017-0605-6

[55] Takiuchi T, Blake EA, Matsuo K, et al. Aspirin use and endometrial cancer risk and survival. Gynecol Oncol. 2018;148(1):222–232. doi: 10.1016/j.ygyno.2017.10.026

[56] Takiuchi T., Blake E.A., Matsuo K., et al. Aspirin use and endometrial cancer risk and survival // Gynecol Oncol. 2018. Vol. 148, N 1. P. 222–232. doi: 10.1016/j.ygyno.2017.10.026

[57] Chen J, Shen P, Zhang X-C, et al. Efficacy and safety profile of celecoxib for treating advanced cancers: a meta-analysis of 11 randomized clinical trials. Clin Ther. 2014;36(8):1253–1263. doi: 10.1016/j.clinthera.2014.06.015

[58] Chen J., Shen P., Zhang X.-c., et al. Efficacy and safety profile of celecoxib for treating advanced cancers: a meta-analysis of 11 randomized clinical trials // Clin Ther. 2014. Vol. 36, N 8. P. 1253–1263. doi: 10.1016/j.clinthera.2014.06.015

[59] Zhang X, Feng Y, Liu X, et al. Beyond a chemopreventive reagent, aspirin is a master regulator of the hallmarks of cancer. J Cancer Res Clin Oncol. 2019;145(6):1387–1403. doi: 10.1007/s00432-019-02902-6

[60] Zhang X., Feng Y., Liu X., et al. Beyond a chemopreventive reagent, aspirin is a master regulator of the hallmarks of cancer // J Cancer Res Clin Oncol. 2019. Vol. 145, N 6. P. 1387–1403. doi: 10.1007/s00432-019-02902-6

[61] Movahedi M, Bishop DT, Macrae F, et al. Obesity, aspirin, and risk of colorectal cancer in carriers of hereditary colorectal cancer: a prospective investigation in the CAPP2 study. J Clin Oncol. 2015;33(31):3591–3597. doi: 10.1200/jco.2014.58.9952

[62] Movahedi M., Bishop D.T., Macrae F., et al. Obesity, aspirin, and risk of colorectal cancer in carriers of hereditary colorectal cancer: a prospective investigation in the CAPP2 study // J Clin Oncol. 2015. Vol. 33, N 31. P. 3591–3597. doi: 10.1200/jco.2014.58.9952

[63] Cao Y, Nishihara R, Wu K, et al. Population-wide impact of long-term use of aspirin and the risk for cancer. J Am Med Assoc Oncol. 2016;2(6):762–769. doi: 10.1001/jamaoncol.2015.6396

[64] Cao Y., Nishihara R., Wu K., et al. Population-wide impact of long-term use of aspirin and the risk for cancer // J Am Med Assoc Oncol. 2016. Vol. 2, N 6. P. 762–769. doi: 10.1001/jamaoncol.2015.6396

[65] Dulai PS, Singh S, Marquez E, et al. Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis. Br Med J. 2016;355:i6188. doi: 10.1136/bmj.i6188

[66] Dulai P.S., Singh S., Marquez E., et al. Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis // Br Med J. 2016. Vol. 355. ID i6188. doi: 10.1136/bmj.i6188

[67] Lu Y, Liu L-L, Liu S-S, et al. Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells. J Transl Med. 2016;14:270. doi: 10.1186/s12967-016-1012-8

[68] Lu Y., Liu L.-L., Liu S.-S., et al. Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells // J Transl Med. 2016. Vol. 14. ID 270. doi: 10.1186/s12967-016-1012-8

[69] Suzuki K, Gerelchuluun A, Hong Z, et al. Celecoxib enhances radiosensitivity of hypoxic glioblastoma cells through endoplasmic reticulum stress. Neuro Oncol. 2013;15(9):1186–1199. doi: 10.1093/neuonc/not062

[70] Suzuki K., Gerelchuluun A., Hong Z., et al. Celecoxib enhances radiosensitivity of hypoxic glioblastoma cells through endoplasmic reticulum stress // Neuro Oncol. 2013. Vol. 15, N 9. P. 1186–1199. doi: 10.1093/neuonc/not062

[71] Yu C, Li W-B, Liu J-B, et al. Autophagy: novel applications of nonsteroidal anti-inflammatory drugs for primary cancer. Cancer Med. 2018;7(2):471–484. doi: 10.1002/cam4.1287

[72] Yu C., Li W.-B., Liu J.-B., et al. Autophagy: novel applications of nonsteroidal anti-inflammatory drugs for primary cancer // Cancer Med. 2018. Vol. 7, N 2. P. 471–484. doi: 10.1002/cam4.1287

[73] Lu Y, Liu X-F, Liu T-R, et al. Celecoxib exerts antitumor effects in HL-60 acute leukemia cells and inhibits autophagy by affecting lysosome function. Biomed Pharmacother. 2016;84:1551–1557. doi: 10.1016/j.biopha.2016.11.026

[74] Lu Y., Liu X.-F., Liu T.-R., et al. Celecoxib exerts antitumor effects in HL-60 acute leukemia cells and inhibits autophagy by affecting lysosome function // Biomed Pharmacother. 2016. Vol. 84. P. 1551–1557. doi: 10.1016/j.biopha.2016.11.026

[75] Zhao Q, Wang Z, Wang Z, et al. Aspirin may inhibit angiogenesis and induce autophagy by inhibiting mTOR signaling pathway in murine hepatocarcinoma and sarcoma models. Oncol Lett. 2016;12(4):2804–2810. doi: 10.3892/ol.2016.5017

[76] Zhao Q., Wang Z., Wang Z., et al. Aspirin may inhibit angiogenesis and induce autophagy by inhibiting mTOR signaling pathway in murine hepatocarcinoma and sarcoma models // Oncol Lett. 2016. Vol. 12, N 4. P. 2804–2810. doi: 10.3892/ol.2016.5017

[77] Han HY, Kim H, Jeong SH, et al. Sulfasalazine induces autophagic cell death in oral cancer cells via Akt and ERK pathways. Asian Pac J Cancer Prev. 2014;15(16):6939–6944. doi: 10.7314/apjcp.2014.15.16.6939

[78] Han H.-Y., Kim H., Jeong S.-H., et al. Sulfasalazine induces autophagic cell death in oral cancer cells via Akt and ERK pathways // Asian Pac. J. Cancer Prev. 2014. Vol. 15, N 16. P. 6939–6944. doi: 10.7314/apjcp.2014.15.16.6939

[79] Mazzanti R, Platini F, Bottini C, et al. Down-regulation of the HGF/MET autocrine loop induced by celecoxib and mediated by P-gp in MDR-positive human hepatocellular carcinoma cell line. Biochem Pharmacol. 2009;78:21–32. doi: 10.1016/j.bcp.2009.03.013

[80] Mazzanti R., Platini F., Bottini C., et al. Down-regulation of the HGF/MET autocrine loop induced by celecoxib and mediated by P-gp in MDR-positive human hepatocellular carcinoma cell line // Biochem. Pharmacol. 2009. Vol. 78, N 1. P. 21–32. doi: 10.1016/j.bcp.2009.03.013

[81] Chu M, Wang T, Sun A, Chen Y. Nimesulide inhibits proliferation and induces apoptosis of pancreatic cancer cells by enhancing expression of PTEN. Exp Ther Med. 2018;16(1):370–376. doi: 10.3892/etm.2018.6191

[82] Chu M., Wang T., Sun A., Chen Y. Nimesulide inhibits proliferation and induces apoptosis of pancreatic cancer cells by enhancing expression of PTEN // Exp Ther Med. 2018. Vol. 16, N 1. P. 370–376. doi: 10.3892/etm.2018.6191

[83] Catarro M, Serrano JL, Ramos SS, et al. Nimesulide analogues: From anti-inflammatory to antitumor agents. Bioorg Chem. 2019;88:102966. doi: 10.1016/j.bioorg.2019.102966

[84] Catarro M., Serrano J.L., Ramos S.S., et al. Nimesulide analogues: From anti-inflammatory to antitumor agents // Bioorg Chem. 2019. Vol. 88. ID 102966. doi: 10.1016/j.bioorg.2019.102966

[85] D’Arcy Y, Mantyh P, Yaksh T, et al. Treating osteoarthritis pain: mechanisms of action of acetaminophen, nonsteroidal anti-inflammatory drugs, opioids, and nerve growth factor antibodies. Postgrad Med. 2021;133(8):879–894. doi: 10.1080/00325481.2021.1949199

[86] D’Arcy Y., Mantyh P., Yaksh T., et al. Treating osteoarthritis pain: mechanisms of action of acetaminophen, nonsteroidal anti-inflammatory drugs, opioids, and nerve growth factor antibodies // Postgrad Med. 2021. Vol. 133, N 8. P. 879–894. doi: 10.1080/00325481.2021.1949199

[87] Kalagova AV, Ailarova NR, Panagov ZG. NSAIDS-gastropathy in patients with rheumatoid arthritis. Bulletin of Science and Education. 2019;(1–1):97–100. EDN: YTIBBR

[88] Калагова А.В., Айларова Н.Р., Панагов З.Г. НПВП-гастропатии у больных ревматоидным артритом // Вестник науки и образования. 2019. № 1–1. С. 97–100. EDN: YTIBBR

[89] Erdes ShF, Rumiantceva DG. Long-term use of non-steroidal anti-inflammatory drugs in the treatment of axial spondylitis. Farmatefa. 2019;26(13):24–29. EDN: HZAPMS doi: 10.18565/pharmateca.2019.13.24-29

[90] Эрдес Ш.Ф., Румянцева Д.Г. Длительное применение нестероидных противовоспалительных препаратов в лечении аксиального спондилоартрита // Фарматека. 2019. № 13. С. 24–29. EDN: HZAPMS doi: 10.18565/pharmateca.2019.13.24-29

[91] Sobolenko DD, Belykh VD, Belyi BU. The deadly influence of non-steroid anti-inflammatory medicines on the mucosa of the small intestinal: the relevance of the problem. Russian Military Medical Academy Reports. 2021;40(S1–1):165–168. EDN: WERMQO

[92] Соболенко Д.Д., Белых В.Д., Белый Б.Ю. Пагубное влияние нестероидных противовоспалительных препаратов на слизистую оболочку тонкого кишечника: актуальность проблемы // Известия Российской Военно-медицинской академии. 2021. Т. 40, № S1–1. С. 165–168. EDN: WERMQO

[93] Hladkykh FV. Preventive and therapeutic strategies of pharmaco-correction gastropathy induced by nonsteroidal anti-inflammatory drugs. Reviews on Clinical Pharmacology and Drug Therapy. 2017;15(4):14–23. EDN: YLLSXK doi: 10.17816/RCF15414-23

[94] Гладких Ф.В. Превентивно-лечебные стратегии фармакоррекции гастропатии, индуцированной нестероидными противовоспалительными препаратами // Обзоры по клинической фармакологии и лекарственной терапии. 2017. Т. 15, № 4. С. 14–23. EDN: YLLSXK doi: 10.17816/RCF15414-23

[95] Andrews EB, Arellano FM, Avorn J, et al. Good pharmacoepidemiology practice (GPP). Moscow: Remedium; 2017. 36 p.

[96] Andrews E.B., Arellano F.M., Avorn J., et al. Надлежащая фармакоэпидемиологическая практика. Москва: Ремедиум, 2017. 36 с.

[97] Mufazalova NA, Valeeva LA, Davletshin RA, et al. Undesirable drug reactions. Drug interactions. Part I. Nonsteroidal anti-inflammatory drugs: Textbook. Ufa: FGBOU VO BGMU of the Ministry of Health of Russia; 2020. 195 p. doi: 10.17513/np.416 (In Russ.)

[98] Муфазалова Н.А., Валеева Л.А., Давлетшин Р.А., и др. Нежелательные лекарственные реакции. Взаимодействие лекарственных средств. Часть I. Нестероидные противовоспалительные препараты: Учебное пособие. Уфа: ФГБОУ ВО БГМУ Минздрава России, 2020. 195 c. doi: 10.17513/np.416

[99] Iskakov BS, Kulumbaeva AB, Yessirkepova GS. NSAID-induced gastropathy in rheumatology practice: current issues in diagnosis and treatment. Bulletin of the Kazakh National Medical University. 2018;(2):486–492. EDN: YWGGMH

[100] Искаков Б.С., Кулембаева А.Б., Есиркепова Г.С. НПВП-индуцированные гастропатии в ревматологической практике: современные вопросы диагностики и лечения // Вестник Казахского национального медицинского университета. 2018. № 2. С. 486–492. EDN: YWGGMH

[101] Horoshun MS, Lazareva AA. Prescribing of non-steroidal anti-inflammatory drugs: benefits and risks. University Therapeutic Journal. 2022;4(1):4–10. doi: 10.56871/3854.2022.69.43.001

[102] Хорошун М.С., Лазарева А.А. Назначение нестероидных противовоспалительных средств: польза и риски // Университетский терапевтический вестник. 2022. Т. 4, № 1. С. 4–10. doi: 10.56871/3854.2022.69.43.001

[103] Maev IV, Osadchuk MA, Krylova YuS, et al. Motilin, vascular endothelial growth factor, and somatostatin expression in the gastric mucosa of patients with NSAID-gastropathy. Russian Journal of Evidence-Based Gastroenterology. 2022;11(4):2231. EDN: OWFHCO doi: 10.17116/dokgastro20221104122

[104] Маев И.В., Осадчук М.А., Крылова Ю.С., и др. Экспрессия мотилина, сосудистого эндотелиального фактора роста и соматостатина в слизистой оболочке антрального отдела желудка у пациентов с НПВП-гастропатией // Доказательная гастроэнтерология. 2022. Т. 11, № 4. С. 22–31. EDN: OWFHCO doi: 10.17116/dokgastro20221104122

[105] National clinical guidelines (summary) of association of rheumatologists of Russia, Russian gastroenterological association, Russian association for the study of pain “rational treatment by non-steroidal anti-inflammatory drugs”: the draft (data of the expert board meeting, Moscow, 01.04.2017). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(5):69–75. EDN: ZHQRYZ

[106] Насонов Е.Л., Ивашкин В.Т., Яхно Н.Н., и др. Проект Национальных клинических рекомендаций (основные положения) Ассоциации ревматологов России, Российской гастроэнтерологической ассоциации, Российского общества по изучению боли «Рациональное использование нестероидных противовоспалительных препаратов» // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017. Т. 27, № 5. С. 69–75. EDN: ZHQRYZ

[107] Lesnaya OA, Rusanova EI, Prokofieva EB, Freire Da Silva T. Rational use of NSAIDs according to clinical guidelines and data from recent studies. Difficult patient. 2019;17(10):31–34. EDN: FEWBVK doi: 10.24411/2074-1995-2019-10072

[108] Лесная О.А., Русанова Е.И., Прокофьева Е.Б., Фрейре да Сильва Т. Рациональное применение НПВП в свете клинических рекомендаций и данных новых исследований // Трудный пациент. 2019. Т. 17, № 10. С. 31–34. EDN: FEWBVK doi: 10.24411/2074-1995-2019-10072

[109] Velts NYu, Zhuravleva EO, Bukatina TM, Kutekhova GV. Nonsteroidal anti-inflammatory drugs: problems of safe use. Safety and Risk of Pharmacotherapy. 2018;6(1):11–18. EDN: YTLADS doi: 10.30895/2312-7821-2018-6-1-11-18

[110] Вельц Н.Ю., Журавлева Е.О., Букатина Т.М., Кутехова Г.В. Нестероидные противовоспалительные препараты: проблемы безопасности применения // Безопасность и риск фармакотерапии. 2018. Т. 6, № 1. С. 11–18. EDN: YTLADS doi: 10.30895/2312-7821-2018-6-1-11-18

[111] Kamchatnov PR, Chugunov AV, Chipova DT, Kazakov AYu. Nonsteroidal anti-inflammatory drugs and the risk of heart failure. RMJ. 2023;(2):88–95. EDN: JHGYGM

[112] Камчатнов П.Р., Чугунов А.В., Чипова Д.Т., Казаков А.Ю. Нестероидные противовоспалительные препараты и риск сердечной недостаточности // РМЖ. 2023. № 2. С. 88–95. EDN: JHGYGM

[113] Chichasova N.V. Current recommendations for the treatment of osteoarthritis. Consilium Medicum. 2016;18(2):124–133.

[114] Чичасова Н.В. Современные рекомендации по лечению остеоартроза // Consilium Medicum. 2016. Т. 18, № 2. С. 124–133.

[115] Balabanova RM, Podryadnova MV. Choice of a nonsteroidal anti-inflammatory drug in ankylosing spondylitis. Modern Rheumatology Journal. 2014;8(4):86–89. EDN: TAKCPX doi: 10.14412/1996-7012-2014-4-86-89

[116] Балабанова Р.М., Подряднова М.В. Выбор нестероидного противовоспалительного препарата при анкилозирующем спондилите // Современная ревматология. 2014. Т. 8, № 4. С. 86–89. EDN: TAKCPX doi: 10.14412/1996-7012-2014-4-86-89

[117] Dydykina IS, Nurbaieva KS, Kovalenko PS, et al. From knowing the mechanism of action to choosing a method for the prevention and treatment of osteoarthritis. RMJ. 2020;28(7):14–18. EDN: LMCZKJ

[118] Дыдыкина И.С., Нурбаева К.C., Коваленко П.С., и др. От знания механизма действия — к принятию решения о выборе подхода к профилактике и лечению остеоартрита // РМЖ. 2020. № 7. С. 14–18. EDN: LMCZKJ

[119] Sсherbak SG, Makarenko SV, Shneider OV, et al. Regenerative Rehabilitation in Injuries of Tendons. Physical and rehabilitation medicine, medical rehabilitation. 2021;3(2):192–206. EDN: FGSGHR doi: 10.36425/rehab70760

[120] Щербак С.Г., Макаренко С.В., Шнейдер О.В., и др. Регенеративная реабилитация при повреждениях сухожилий // Физическая и реабилитационная медицина, медицинская реабилитация. 2021. Т. 3, № 2. С. 192–206. EDN: FGSGHR doi: 10.36425/rehab70760

[121] Scarabin P-Y, Oger E, Plu-Bureau G, EStrogen and Thromboembolism Risk Study Group. Differential association of oral and transdermal oestrogenreplacement therapy with venous thromboembolism risk. Lancet. 2003;362(9382):428–432. doi: 10.1016/S0140-6736(03)14066-4

[122] Scarabin P.-Y., Oger E., Plu-Bureau G., Estrogen and Thromboembolism Risk Study Group. Differential association of oral and transdermal oestrogenreplacement therapy with venous thromboembolism risk // Lancet. 2003. Vol. 362, N 9382. P. 428–432. doi: 10.1016/S0140-6736(03)14066-4

[123] Rebrov AP. Pain, NSAIDs, and chronic kidney disease: a difficult relationship. South Russian Journal of Therapeutic Practice. 2022;3(2): 25–31. EDN: MSOHXN doi: 10.21886/2712-8156-2022-3-2-25-31

[124] Ребров А.П. Боль, нестероидные противовоспалительные препараты и хроническая болезнь почек: непростые взаимоотношения // Южно-Российский журнал терапевтической практики. 2022. Т. 3, № 2. С. 25–31. EDN: MSOHXN doi: 10.21886/2712-8156-2022-3-2-25-31

[125] Panevin TS, Voronina NV. Kidney damage in rheumatic diseases: new prospects for nephroprotection. Far East Medical Journal. 2022;(3):129–136. EDN: KQYMJW doi: 10.35177/1994-5191-2022-3-20

[126] Паневин Т.С., Воронина Н.В. Поражение почек при ревматических заболеваниях: новые перспективы нефропротекции // Дальневосточный медицинский журнал. 2022. № 3. С. 129–136. EDN: KQYMJW doi: 10.35177/1994-5191-2022-3-20

[127] Domingo C, Palomares O, Sandham DA, et al. The prostaglandin D2 receptor 2 pathway in asthma: a key player in airway inflammation. Respir Res. 2018;19:189. doi: 10.1186/s12931-018-0893-x

[128] Domingo C., Palomares O., Sandham D.A., et al. The prostaglandin D2 receptor 2 pathway in asthma: a key player in airway inflammation // Respir Res. 2018. Vol. 19. ID 189. doi: 10.1186/s12931-018-0893-x

[129] Pronina IV. Leukotrienes and a modern view of the use of their antagonists in the treatment of bronchial asthma. International Student Scientific Bulletin. 2020;(2):20. EDN: WVREKP

[130] Пронина И.В. Лейкотриены и современный взгляд на применение их антагонистов в лечении бронхиальной астмы // Международный студенческий научный вестник. 2020. № 2. ID 20. EDN: WVREKP

[131] Zharkih МА, Jablonsky SV, Mokronosova MA. Leukotrienes and antileukotriene drugs in allergic rhinitis. Pediatric pharmacology. 2009;6(5):20–29. EDN: KYLVET

[132] Жарких М.А., Яблонский С.В., Мокроносова М.А. Значение лейкотриенов и антилейкотриеновых препаратов при аллергическом рините // Педиатрическая фармакология. 2009. Т. 6, № 5. С. 20–29. EDN: KYLVET

[133] Kniazheskaya NP, Chuchalin AG. Current aspects of aspirin-induced bronchial asthma. Pulmonologiya. 1999;(2):91–94.

[134] Княжеская Н.П., Чучалин А.Г. Современные аспекты аспириновой бронхиальной астмы // Пульмонология. 1999. № 2. С. 91–94.

[135] Karateyev AYe, Zhuravlyova MV. Analysis of spontaneous reports provided by Russian physicians regarding adverse reactions occurring after administration of nimesulide: hepatotoxic complications occur very rarely. Effective pharmacotherapy. 2015;(2):4–12.

[136] Каратеев Е.А., Журавлева М.В. Анализ спонтанных сообщений российских врачей о неблагоприятных реакциях, возникших на фоне приема нимесулида: гепатотоксические осложнения очень редки // Эффективная фармакотерапия. 2015. № 2. С. 4–12.

[137] Caiazzo E, Ialenti A, Cicala C. The relatively selective cyclooxygenase2 inhibitor nimesulide: What’s going on? Eur J Pharmacol. 2019;848:105–111. doi: 10.1016/j.ejphar.2019.01.044

[138] Caiazzo E., Ialenti A., Cicala C. The relatively selective cyclooxygenase2 inhibitor nimesulide: What’s going on? // Eur J Pharmacol. 2019. Vol. 848. P. 105–111. doi: 10.1016/j.ejphar.2019.01.044

[139] Yang Z, Ji W, Li M, et al. Protective effect of nimesulide on acute lung injury in mice with severe acute pancreatitis. Am J Transl Res. 2019;11(9):6024–6031.

[140] Yang Z., Ji W., Li M., et al. Protective effect of nimesulide on acute lung injury in mice with severe acute pancreatitis // Am J Transl Res. 2019. Vol. 11, N 9. P. 6024–6031.

[141] Podobed VM. Zinc Сarnosin: a new formula of gastroprotection and making up zinc deficiency. Matters of certification and professional development. 2015;(2):17–20.

[142] Подобед В.М. Цинк Карнозин: новая формула гастропротекции и восполнения дефицита цинка // Вопросы аттестации и повышения квалификации. 2015. № 2. С. 17–20.

[143] Karkishchenko VN, Pomytkin IA, Karkishchenko NN. Peptide activators of sirtuin 1 (SIRT1) expression: a new class of anti-inflammatory drugs. Experimental and clinical pharmacology. 2023;86(11S):115. EDN: VVCMKY doi: 10.30906/ekf-2023-86s-69b (In Russ.)

[144] Каркищенко В.Н., Помыткин И.А., Каркищенко Н.Н. Пептидные активаторы экспрессии сиртуина 1 (SIRT1): новый класс противовоспалительных препаратов // Экспериментальная и клиническая фармакология. 2023. Т. 86, № 11S. ID 115. EDN: VVCMKY doi: 10.30906/ekf-2023-86s-69b

RIGHTS & PERMISSIONS

ECO-vector LLC